Partner

Articles & Insights / Cleaning Validation

Cleaning Validation That Connects Residue Limits to Sampling and Recovery

Cleaning validation depends on more than a low laboratory result. The programme must connect a scientifically justified residue limit with a repeatable cleaning process, representative sampling and a method capable of measuring what remains.

Stabicon Life Sciences3 min read

Accreditations, approvals & registrations

  • Prequalified by WHO, Geneva

    One of the Only 6 Commercial Testing Facilities in India to have a WHO Geneva Approval

  • Accredited by ISO/IEC 17025:2017 (NABL)

  • Approved by FSSAI

  • Approved by CDSCO, India

  • Facility Registered with FDA, Karnataka

  • Registered with DSIR

  • Registered with AYUSH

All articles

What this article helps you consider

  • Establish the hazard and the control objective
  • Translate the limit to the real equipment train
  • Select complementary sampling approaches

Establish the hazard and the control objective

In shared pharmaceutical equipment, assess the potential transfer of one product or substance into the next. Health-based exposure limits, or HBELs, provide toxicological input to the risk assessment. They should be established by appropriately qualified experts using relevant data; a laboratory should not invent a permitted exposure from a convenient analytical limit.

WHO, EMA and Health Canada describe risk-based approaches to cleaning validation. EMA also distinguishes a calculated HBEL from operational cleaning limits and alert levels that maintain the process under control. An exposure calculation is therefore one input to the cleaning strategy, rather than permission to operate routinely close to a toxicological ceiling. R38R39R40

Translate the limit to the real equipment train

The relationship between allowable carryover and a sampled surface depends on the next product’s batch size and daily dose, the shared equipment and the allocation assumptions. Record the units and the product sequence. The worst case may change when a different following product or a smaller batch is introduced.

A uniformly distributed residue assumption is convenient for calculation but may not describe actual contamination. Gaskets, dead spaces, transfer lines and poorly drained areas can retain local deposits. Use equipment knowledge and cleaning experience to identify where sampling will be most informative.

Select complementary sampling approaches

Swabbing examines a defined accessible area and can target difficult-to-clean locations. Rinse sampling can cover internal areas that are less accessible, but recovery depends on wetting, solubility and the flow path. A low rinse result may coexist with a deposit that the rinse does not reach or dissolve.

Visual inspection adds useful evidence when performed under suitable conditions by trained personnel. It has limitations at low residue levels and on inaccessible surfaces. The illustration shows how visual, swab and rinse evidence can complement one another; it assigns no universal acceptance criterion to any approach.

Explore the scienceCleaning Validation

Three complementary ways to examine cleaning

InspectTargeted swabRinse
Visual inspection

Suitable conditions and trained personnel make visible-residue observations useful, with limitations.

Conceptual explanation. No product result, acceptance criterion or universal regulatory sequence is established by this illustration.

Visual inspection, targeted swabbing and rinse sampling provide complementary evidence. Sampling recovery and analytical suitability must be demonstrated for the relevant surfaces, residues and matrices.

Demonstrate recovery from relevant surfaces

Recovery studies should represent the analyte, surface and sampling procedure. Evaluate the full sequence from residue deposition to extraction and analysis where appropriate. Stainless steel results do not automatically establish recovery from elastomers, plastics or coated surfaces.

A hypothetical surface spike of 10 micrograms that yields 7 micrograms indicates 70% recovery under the tested conditions. This does not make 70% a universal acceptable recovery. Determine whether performance is sufficiently consistent and sensitive for the decision, and specify how recovery is handled in calculations without applying the correction twice.

Develop an analytical method for the actual residue

A product assay may be unsuitable at cleaning-residue concentrations or in the swab and detergent matrix. Evaluate specificity, extraction, solution stability, quantitation capability and interferences. A nonspecific method such as total organic carbon may be useful in a justified programme, but the response cannot identify which organic substance produced it.

Cleaning agents, degradation products and microbiological risks may need separate controls. A method directed only at the parent active can miss a transformed residue. Select measurements using knowledge of the soil and cleaning chemistry, rather than assuming every residue behaves like the original formulation.

Validate the process under relevant conditions

Assess cleaning parameters, dirty and clean hold times, operator variability and product campaigns where relevant. A successful execution under ideal conditions does not establish routine repeatability. Define deviations, ongoing verification and changes that trigger reassessment, including new products, equipment modifications and revised toxicological information.

Stabicon can support residue-method development, recovery studies and analytical testing within a clearly defined cleaning-validation programme. Responsibilities for toxicological assessment, facility controls and process approval should remain explicit in the project scope.

References & further reading

Read the source in its stated scope. Requirements, amendments and compendial editions depend on the product and target market. Draft guidance is identified separately.

  1. R38
    WHO Points to Consider When Including HBELs in Cleaning Validation

    WHO Technical Report Series 1033, Annex 2, 2021.

  2. R39
    EMA Questions and Answers on HBELs and Cross Contamination

    Pharmaceutical implementation guidance. Distinguishes exposure assessment from operational cleaning controls.

  3. R40
    Health Canada Cleaning Validation Guide GUI 0028

    Official guide. Sampling, recovery, risk assessment and ongoing controls.

  4. R04
    ICH Q2 R2 Validation of Analytical Procedures

    Final guideline adopted November 2023. Analytical validation framework.

From insight to a defined programme

Bring your next technical question.

Share your formulation, testing objective or development challenge. Stabicon can review the context and define a suitable scope of work.

Discuss this topic with Stabicon

Continue reading

Related scientific perspectives.

Stabicon Life Sciences

Science-Led Formulations. Scalable Health Platforms.

Offices

Corporate Office

22, 7th Cross, Jaibharath Nagar, Bengaluru 560 033, Karnataka, India

Research & Development

28, Bommasandra Industrial Area, 4th Phase, Jigani Hobli, Anekal Taluk, Bengaluru 560 099, Karnataka, India

Newsletter

Quarterly briefings on platforms, science & partnerships.

No spam. Request a consent withdrawal at bd@stabicon.com.

Press Kit

Logos, company information & spokesperson details – available from our media team.

Request Press Kit

Accreditations

Prequalified by WHO, GenevaAccredited by ISO/IEC 17025:2017 (NABL)Approved by FSSAIApproved by CDSCO, IndiaFacility Registered with FDA, KarnatakaRegistered with DSIRRegistered with AYUSHOne of the Only 6 Commercial Testing Facilities in India to have a WHO Geneva Approval

Disclaimer: The information provided on this website is for educational and informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. These statements have not been evaluated by the Food and Drug Administration (FDA). This product is not intended to diagnose, treat, cure, or prevent any disease. Product packaging and materials may vary from those shown on our website. We recommend that you do not rely solely on the information presented and that you always read labels, warnings, and directions before using or consuming a product.

© 2026 Stabicon Life Sciences Pvt. Ltd. All rights reserved.

Science-Led Formulations. Scalable Health Platforms.

Admin